New research reveals that people who stop using blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People using these medications need to be cognizant of the danger of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass in about one and a half years.
Comparing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting generally experience a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Experts propose the mode of action of the jabs explains the accelerated weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals argue that, considering the significant potential of relapse, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who state that the findings "highlight the persistent character of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication explain a sudden return of appetite.
"I experienced something flipping and you become starving," recalled one woman.
This difficulty is exacerbated if patients have not developed sustainable dietary or behavioural changes during therapy.
Growing Interest
Recent estimates show that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is more common among females compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are powerful agents for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated behavioural management.
